SCHEMBL7185735

SCHEMBL7185735

N#Cc1ccc(N[C@H]2CC[C@H](O)CC2)c(N)c1

nearest known ligand 0.47

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
PIM1 P11309 1/20 0.41
PRKCQ Q04759 1/20 0.40
IRAK4 Q9NWZ3 4/20 0.40
CHUK O15111 1/20 0.40
HSP90AA1 P07900 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185729 1.00 KDM4E (0.47) KDM4EALDH1A1GAAPIM1PRKCQ
SCHEMBL8250121 0.92 KDM4E (0.53) KDM4EALDH1A1GAAIRAK4ALOX15
SCHEMBL27437365 0.86 KDM4E (0.50) KDM4EALDH1A1GAAPIM1IRAK4
SCHEMBL7182013 0.86 KDM4E (0.51) KDM4EALDH1A1GAAPIM1IRAK4
SCHEMBL29673232 0.86 KDM4E (0.51) KDM4EALDH1A1GAAPIM1IRAK4
SCHEMBL7187273 0.85 KDM4E (0.54) KDM4EALDH1A1GAAPIM1IRAK4
SCHEMBL6644188 0.85 KDM4E (0.54) KDM4EALDH1A1GAAPIM1IRAK4
SCHEMBL16444870 0.83 KDM4E (0.46) KDM4EALDH1A1GAAIRAK4ALOX15
SCHEMBL16444868 0.83 KDM4E (0.46) KDM4EALDH1A1GAAIRAK4ALOX15
SCHEMBL7178365 0.82 KDM4E (0.47) KDM4EALDH1A1GAAIRAK4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3204375-B1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) REVIRAL LTD (GB) 2019-02-13 EP disclosed
US-10106539-B2 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) ReViral Limited (GB) 2018-10-23 US disclosed
US-20170305908-A1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) ReViral Limited (GB) 2017-10-26 US disclosed
US-6582351-B1 Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305908-A1 SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) NR3C2, SAV1, ACE2 KDM4E 4148/4885ALDH1A1 1371/4885GAA 4492/4885
US-10106539-B2 Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) SPTBN1, NR3C2, SPNS2 KDM4E 4216/4885ALDH1A1 1325/4885GAA 4434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.